{
  "id": 19398461,
  "title": "Tarsus at Guggenheim conference: xdemvy growth, pipeline widen",
  "url": "https://urgent.news/2026/11/10/tarsus-at-guggenheim-conference-xdemvy-growth-pipeline-widen",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T21:24:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/tarsus-at-guggenheim-conference-xdemvy-growth-pipeline-widen-93CH-5016910"
  },
  "original_language": "en",
  "account": "At the 3rd Annual Guggenheim Healthcare Innovation Conference on November 10, 2026, Tarsus Pharmaceuticals (TARS) showcased robust commercial growth for its XDEMVY product and a broader expansion into new eye-care markets. Management highlighted increased sales, improved marketing returns, and an expanding patient base, while acknowledging seasonal pressures, acquisition-related costs, and a pipeline still in development.\n\nQ3 revenue saw a 64% year-over-year increase, prompting a slight upward adjustment in full-year guidance. XDEMVY continues to gain market share in treating demodex blepharitis, with one-third of patients now aware of the condition and requesting their doctors' input. Tarsus is broadening the product's usage to include patients with ocular surface issues, comorbidities, and recurrent styes alongside demodex blepharitis.\n\nThe company maintains a $2 billion U.S. peak sales projection for XDEMVY, with a 20% stabilization in the retreatment rate. Pipeline initiatives now include gildeuretinol for Stargardt disease, IRX-101 for pre-op antisepsis, and research into ocular rosacea and Lyme disease. Neera Clase, Tarsus's chief commercial officer, reported that Q3 revenue growth of 64% was broad across the XDEMVY franchise, and the company anticipates continued strength in Q4 despite potential winter weather disruptions.\n\nSeasonal patterns, such as lower refill activity in Q1 and quarterly resets in new Rx product cycles, were noted as part of the business landscape. Tarsus mentioned that back half-year retreatments could rise as some patients meet deductibles. The company attributed part of its increased selling, general, and administrative spending to integration expenses from its acquisition of Alkeus, which were not included in the adjusted figure. R&D spending is expected to rise modestly in 2025 as new studies commence.\n\nTarsus's commercial playbook remains effective, and the company is leveraging multiple channels to raise awareness of demodex blepharitis. Awareness among patients has risen, with one in three now identifying the condition and discussing it with their physicians. Slit lamp diagnosis is becoming more commonplace in eye-care practices. Tarsus added 20 Key Account Leaders in 2024 and recorded its first full quarter of operations in Q3, focusing on route management, visit frequency, and messaging to prescribers.\n\nManagement emphasized that XDEMVY is expanding its reach beyond the initial symptomatic demodex blepharitis patient population. The company is targeting asymptomatic patients who require ocular surface optimization prior to surgery and patients with comorbidities. A new segment of patients with recurrent styes, co-occurring with demodex blepharitis, has emerged, demonstrating strong treatment outcomes. Abstracts on this new patient group were presented at the American Academy of Optometry, highlighting the growing evidence base supporting XDEMVY's use across various patient types.\n\nThe company unveiled gildeuretinol, acquired from Alkeus Pharmaceuticals, as a potential breakthrough asset for treating Stargardt disease, a vision-threatening condition with no approved treatments. Tarsus estimates around 36,000 diagnosed patients and up to 86,000 undiagnosed individuals in the U.S. The NORTHSTAR Phase 3 trial for gildeuretinol, launched in June/July 2024, will assess structural and functional endpoints, including lesion size reduction and visual acuity improvements. FDA alignment was secured before the trial's inception, with no anticipated design changes.\n\nManagement underscored that gildeuretinol represents a category-creating asset within Tarsus's model of creating new markets where none exist. They noted the potential for an interim data readout in the future, but the comprehensive data package remains several years away. Additionally, Tarsus discussed IRX-101, an oral pre-operative ocular antiseptic acquired from iRenix, targeting around 11 million procedures annually in the U.S. With the current standard of care being Betadine, Tarsus believes IRX-101 could reduce pain and corneal toxicity, potentially introducing a new standard of care to the retinal specialist community. Two other oral products are also in pursuit of FDA approval, but Tarsus is more focused on market development rather than competing on being the first to market.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}